Data for: A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer
收藏Mendeley Data2024-06-25 更新2024-06-27 收录
下载链接：
https://data.mendeley.com/datasets/yj4byrkjmj
下载链接
链接失效反馈官方服务：
资源简介：
Protocol and SAP
创建时间：
2024-01-23
